for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Shionogi & Co Ltd

4507.T

Latest Trade

5,752.00JPY

Change

-136.00(-2.31%)

Volume

1,146,400

Today's Range

5,752.00

 - 

5,850.00

52 Week Range

4,761.00

 - 

6,449.00

As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
5,888.00
Open
5,849.00
Volume
1,146,400
3M AVG Volume
24.83
Today's High
5,850.00
Today's Low
5,752.00
52 Week High
6,449.00
52 Week Low
4,761.00
Shares Out (MIL)
301.46
Market Cap (MIL)
1,834,619.00
Forward P/E
17.04
Dividend (Yield %)
1.83

Next Event

Q1 2022 Shionogi & Co Ltd Earnings Release

Latest Developments

More

Viiv Healthcare Announces FDA Approval Of Cabenuva For HIV Treatment

Aim Immunotech Shifts Focus To Begin Clinical Trials For Ampligen As An Early Onset Therapy For Covid-19 In Cancer Patients

Viiv Healthcare Says CHMP Positive Opinion For Dispersible-Tablet Formulation Of Dolutegravir

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Shionogi & Co Ltd

Shionogi & Co., Ltd. is a Japan-based pharmaceutical company mainly engaged in the research, development, purchase, manufacture and sale of pharmaceuticals, as well as pharmaceutical-related businesses. The prescription drug business is engaged in the development of eight new drugs including hypercholesterolemia treatment drugs Crestor, antihypertensive drugs Ilbetan Family (Irbetan, Aimix, Iltra) and antidepressant drugs Sinbalta. The Company is engaged in the provision of information to contribute to medical care by maximizing its products. The over-the-counter (OTC) pharmaceutical business handles products tailored to customers' lifestyles. The in-vitro diagnostics business is engaged in the sale of products, as well as the provision of information on infectious diseases, cardiovascular diseases and allergic diseases. The Company mainly provides its products and services in Japan, Europe and North America markets.

Industry

Major Drugs

Contact Info

3-1-8, Dosho-machi, Chuo-ku

OSAKA-SHI, OSK

541-0045

Japan

+81.6.62022161

https://www.shionogi.co.jp/

Executive Leadership

Isao Teshirogi

President, Chief Executive Officer, Representative Director

Takuko Sawada

Vice President, Chief Director of Health & Care Strategy, Director

Koji hanasaki

Senior Executive Officer, Chief Director of Business Strategy

Kazuhiro Hatanaka

Senior Executive Officer, Chief Director of Pharmaceutical Business

Toshinobu Iwasaki

Senior Executive Officer, Chief Director of Pharmaceutical Development

Key Stats

2.33 mean rating - 15 analysts
Sell
Hold
Buy
Revenue (MM, JPY)

2019

0.4K

2020

0.3K

2021

0.3K

2022(E)

0.3K
EPS (JPY)

2019

424.308

2020

392.800

2021

365.030

2022(E)

342.066
Price To Earnings (TTM)
16.15
Price To Sales (TTM)
6.17
Price To Book (MRQ)
2.10
Price To Cash Flow (TTM)
14.46
Total Debt To Equity (MRQ)
1.56
LT Debt To Equity (MRQ)
1.16
Return on Investment (TTM)
13.40
Return on Equity (TTM)
11.97

Latest News

Latest News

Japan's Shionogi partners with universities to develop visual coronavirus test

Shionogi & Co Ltd said it is partnering with Japanese universities to develop a saliva test for coronavirus that can yield visual results in 25 minutes.

BRIEF-Shionogi & Co Ltd - Agreed With Nihon Unversity, Others On Licence Agreement For New Rapid Diagnostic Method For Viruses Including Novel Coronavirus

* SHIONOGI & CO LTD - AGREED WITH NIHON UNVERSITY, OTHERS ON LICENCE AGREEMENT FOR NEW RAPID DIAGNOSTIC METHOD FOR VIRUSES INCLUDING NOVEL CORONAVIRUS Source text for Eikon: Further company coverage:

BRIEF-FDA Accepts Shionogi's Supplemental New Drug Application With Priority Review For Fetroja

* FDA ACCEPTS SHIONOGI’S SUPPLEMENTAL NEW DRUG APPLICATION WITH PRIORITY REVIEW FOR FETROJA® (CEFIDEROCOL) FOR THE TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA AND VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA

BRIEF-Tetra Therapeutics Enters Into Definitive Merger Agreement To Be Acquired By Shionogi

* TETRA THERAPEUTICS ENTERS INTO DEFINITIVE MERGER AGREEMENT TO BE ACQUIRED BY SHIONOGI

BRIEF-Shionogi & Co Ltd - Notice Regarding Tetra Becoming A Wholly Owned Subsidiary Of Shionogi

* NOTICE REGARDING TETRA BECOMING A WHOLLY OWNED SUBSIDIARY OF SHIONOGI

BRIEF-Shionogi Accelerates Development Of Potential Covid-19 Treatments And Vaccine

* SHIONOGI ACCELERATES DEVELOPMENT OF POTENTIAL COVID-19 TREATMENTS AND VACCINE

BRIEF-Shionogi & Co Ltd - Will Develop A Prophylactic Vaccine For Covid-19

* DECIDED TO POSITION THE DEVELOPMENT OF COVID-19 VACCINE AS A TOP-PRIORITY PROJECT, ALONGSIDE DISCOVERY OF COVID-19 THERAPEUTIC DRUGS

BRIEF-Shionogi & Co Ltd - Shionogi And Micro Blood Science Inc Initiated Discussions For A Business Partnership

* SHIONOGI AND MICRO BLOOD SCIENCE INC INITIATED DISCUSSIONS FOR A BUSINESS PARTNERSHIP

BRIEF-Tetra Therapeutics And Shionogi Announce Expanded Alliance

* TETRA THERAPEUTICS- CO,SHIONOGI WILL WORK TOGETHER TO DEVELOP & COMMERCIALIZE BPN14770

BRIEF-Shionogi's FETROJA Now Available For Treatment Of Complicated Urinary Tract Infections In U.S.

* SHIONOGI'S FETROJA (CEFIDEROCOL) NOW AVAILABLE FOR TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS IN U.S. Source text for Eikon: Further company coverage:

As steep patent cliff looms, Shionogi moves to develop its own U.S. sales staff

For much of its 141-year history, Japan's Shionogi & Co Ltd <4507.T> has played safe when selling its drugs in the United States and other overseas markets - relying on bigger partners to promote its products and avoiding the cost of maintaining a large sales force.

Japanese drugmaker Shionogi sees record profit on royalty income

Japanese drugmaker Shionogi & Co Ltd forecast a 6.1 percent jump in full-year operating profit to what would be its fifth straight record high, underpinned by strong royalty income from its HIV drugs.

Japanese drugmaker Shionogi sees profit rising on royalty income

Japanese drugmaker Shionogi & Co Ltd expects its annual operating profit to rise 6.1 percent, it said on Thursday, underpinned by strong royalty income from its HIV drugs.

RPT-BRIEF-Shionogi & Co Ltd Announces Agreements On Collaborative Research With Peptidream For New Peptide Drug Conjugate(Pdc) Discovery

* SHIONOGI & CO LTD ANNOUNCES AGREEMENTS ON COLLABORATIVE RESEARCH WITH PEPTIDREAM INC FOR NEW PEPTIDE DRUG CONJUGATE (PDC) DISCOVERY Source text for Eikon: Further company coverage:

Shionogi aims to double flu-drug market with FDA-approved treatment

Japan's Shionogi & Co Ltd aims to double the global market for flu treatment with its drug Xofluza, the first flu drug approved by the U.S. Food and Drug Administration agency in nearly 20 years, its chief executive said.

FDA approves first new flu drug in almost two decades

Japan's Shionogi & Co Ltd and Swiss drugmaker Roche won U.S. Food and Drug Administration (FDA) approval for their flu treatment, the first new flu drug approved by the agency in nearly 20 years.

FDA approves blood disorder drug made by Japan's Shionogi

The U.S. Food and Drug Administration on Tuesday approved Japan-based Shionogi & Co Ltd's treatment for low blood-platelet count or thrombocytopenia in patients with chronic liver disease.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up